Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.
作者信息
Sarma Phulen, Prajapat Manisha, Avti Pramod, Kaur Hardeep, Kumar Subodh, Medhi Bikash
机构信息
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
Indian J Pharmacol. 2020 Jan-Feb;52(1):1-5. doi: 10.4103/ijp.IJP_119_20. Epub 2020 Mar 11.
Abstract
摘要
相似文献
1
Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.2019新型冠状病毒治疗的治疗选择：循证方法
Indian J Pharmacol. 2020 Jan-Feb;52(1):1-5. doi: 10.4103/ijp.IJP_119_20. Epub 2020 Mar 11.
2
Sofosbuvir for COVID-19 infection: A potential candidate.索磷布韦用于治疗新型冠状病毒肺炎感染：一个潜在的候选药物。
Indian J Pharmacol. 2020 May-Jun;52(3):232-233. doi: 10.4103/ijp.IJP_675_20. Epub 2020 Aug 4.
3
Is the type of diabetes treatment relevant to outcome of COVID-19?糖尿病治疗类型与新型冠状病毒肺炎的预后有关吗？
J Diabetes. 2020 Jul;12(7):486-487. doi: 10.1111/1753-0407.13047.
4
Statins in coronavirus outbreak: It's time for experimental and clinical studies.冠状病毒爆发中的他汀类药物：是时候进行实验和临床研究了。
Pharmacol Res. 2020 Jun;156:104803. doi: 10.1016/j.phrs.2020.104803. Epub 2020 Apr 11.
5
Covid-19 treatment update: follow the scientific evidence.新冠病毒疾病治疗进展：遵循科学证据。
J Thromb Thrombolysis. 2020 Jul;50(1):43-53. doi: 10.1007/s11239-020-02120-9.
6
COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response.新型冠状病毒肺炎与相对血管紧张素转换酶2缺乏：在疾病严重程度和治疗反应中的作用
Open Heart. 2020 Jun;7(1). doi: 10.1136/openhrt-2020-001302.
7
Coronavirus disease 2019 infection and the cardiovascular system.2019冠状病毒病感染与心血管系统
J Cardiovasc Med (Hagerstown). 2020 Jun;21(6):403-405. doi: 10.2459/JCM.0000000000000980.
8
Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients.新冠病毒疾病（COVID-19）患者使用羟氯喹的精神科影响
Indian J Pharmacol. 2020 May-Jun;52(3):229-231. doi: 10.4103/ijp.IJP_595_20. Epub 2020 Aug 4.
9
Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus.营养保健品有潜力增强对包括流感病毒和冠状病毒在内的RNA病毒的1型干扰素反应。
Prog Cardiovasc Dis. 2020 May-Jun;63(3):383-385. doi: 10.1016/j.pcad.2020.02.007. Epub 2020 Feb 12.
10
Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.新型冠状病毒感染非危重症患者的深静脉血栓形成。
Thromb Res. 2020 Aug;192:27-28. doi: 10.1016/j.thromres.2020.05.015. Epub 2020 May 14.
引用本文的文献
1
Safety of Hydroxychloroquine for COVID-19 Prophylaxis in Healthcare Workers: A Cross-Sectional Study.羟氯喹用于医护人员预防新型冠状病毒肺炎的安全性：一项横断面研究
Cureus. 2025 Feb 25;17(2):e79660. doi: 10.7759/cureus.79660. eCollection 2025 Feb.
2
Stability, homogeneity and measurement uncertainty estimation of PVP-I solutions for the application on oro and nasopharynx against SARS-CoV-2.用于针对 SARS-CoV-2 的口咽和鼻咽应用的 PVP-I 溶液的稳定性、均一性和测量不确定度评估。
Sci Rep. 2024 Mar 27;14(1):7268. doi: 10.1038/s41598-024-52346-3.
3
Insight into the mechanisms of coronaviruses evading host innate immunity.深入了解冠状病毒逃避宿主固有免疫的机制。
Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166671. doi: 10.1016/j.bbadis.2023.166671. Epub 2023 Feb 27.
4
In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease.计算机模拟评估天然类黄酮作为冠状病毒病潜在抑制剂的研究
Molecules. 2022 Sep 27;27(19):6374. doi: 10.3390/molecules27196374.
5
Effectiveness of Plasmapheresis Treatment in the Treatment of Patients with COVID-19 Disease.血浆置换疗法在治疗新型冠状病毒肺炎患者中的有效性
Med J Islam Repub Iran. 2022 Jul 25;36:83. doi: 10.47176/mjiri.36.83. eCollection 2022.
6
Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity.关于包括COVID-19大流行在内的各种病毒感染、靶向抗病毒药物和疫苗的重要观点。
Mol Biomed. 2022 Jul 15;3(1):21. doi: 10.1186/s43556-022-00078-z.
7
Development of an efficient reproducible cell-cell transmission assay for rapid quantification of SARS-CoV-2 spike interaction with hACE2.开发一种高效可重复的细胞-细胞传递测定法，用于快速定量 SARS-CoV-2 刺突与人 ACE2 的相互作用。
Cell Rep Methods. 2022 Jul 18;2(7):100252. doi: 10.1016/j.crmeth.2022.100252. Epub 2022 Jun 20.
8
COVID-19-associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis.COVID-19 相关的鼻眶脑毛霉菌病：系统评价、荟萃分析和荟萃回归分析。
Indian J Pharmacol. 2021 Nov-Dec;53(6):499-510. doi: 10.4103/ijp.ijp_839_21.
9
SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review.SARS-CoV-2、感染、传播、转录、翻译、蛋白质和治疗：综述。
Int J Biol Macromol. 2021 Dec 15;193(Pt B):1249-1273. doi: 10.1016/j.ijbiomac.2021.10.172. Epub 2021 Oct 28.
10
An Examination of the Factors Affecting Community Pharmacists' Knowledge, Attitudes, and Impressions About the COVID-19 Pandemic.影响社区药剂师对新冠疫情的知识、态度和印象的因素考察
Turk J Pharm Sci. 2021 Oct 28;18(5):530-540. doi: 10.4274/tjps.galenos.2020.01212.
本文引用的文献
1
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).2019新型冠状病毒（2019-nCoV）的治疗选择。
Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0.
2
Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province.湖北省三级医院新型冠状病毒病例的临床特征。
Chin Med J (Engl). 2020 May 5;133(9):1025-1031. doi: 10.1097/CM9.0000000000000744.
3
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.临床证据不支持使用皮质类固醇治疗2019新型冠状病毒肺炎肺损伤。
Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
4
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.四例新型冠状病毒肺炎患者采用中西医结合治疗的临床特点和治疗经过。
Biosci Trends. 2020 Mar 16;14(1):64-68. doi: 10.5582/bst.2020.01030. Epub 2020 Feb 9.
5
Reducing mortality from 2019-nCoV: host-directed therapies should be an option.降低2019新型冠状病毒所致死亡率：宿主导向疗法应成为一种选择。
Lancet. 2020 Feb 22;395(10224):e35-e36. doi: 10.1016/S0140-6736(20)30305-6. Epub 2020 Feb 5.
6
Clinical Features and Treatment of 2019-nCov Pneumonia Patients in Wuhan: Report of A Couple Cases.武汉2019新型冠状病毒肺炎患者的临床特征及治疗：2例报告
Virol Sin. 2020 Jun;35(3):330-336. doi: 10.1007/s12250-020-00203-8. Epub 2020 Feb 7.
7
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.巴瑞替尼作为2019新型冠状病毒急性呼吸道疾病的潜在治疗方法。
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
8
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
9
2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate - a word of caution.2019新型冠状病毒（2019-nCoV）：估计病死率——一则警示
Swiss Med Wkly. 2020 Feb 7;150:w20203. doi: 10.4414/smw.2020.20203. eCollection 2020 Jan 27.
10
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).新型冠状病毒（2019-nCoV）感染的肺炎快速诊治指南（标准版）。
Mil Med Res. 2020 Feb 6;7(1):4. doi: 10.1186/s40779-020-0233-6.
Zotero 插件